Navigation Links
Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
Date:3/13/2008

utely inflamed areas, nor used to reduce the swelling of bites or stings. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated. Furosemide, the benzodiazepines, and phenytoin are incompatible with hyaluronidase. Please see accompanying package insert at http://www.hylenex.com for full Prescribing Information.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, (i) statements concerning the company's ability to execute on its strategy and (ii) clinical trial results and the conclusions drawn from such trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forw
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Kingston, Ontario (PRWEB) May 21, 2015 ... entered into an exclusive North American distribution agreement ... microbiology testing system. , With more than 160 ... of products and services for laboratory and production ... choice, operational excellence and differentiated services to enable ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
(Date:5/20/2015)... , May 20, 2015  Marc Tessier-Lavigne, president ... gift of $100 million from The Marie-Josée and ... new laboratory building that will be the centerpiece ... Marie-Josée and Henry R. Kravis Research Building, two ... Drive, spanning approximately three city blocks following the ...
(Date:5/20/2015)... TRIANGLE PARK, North Carolina , ... weltweit führende Unternehmen für klinische Logistik ... Finanzergebnisse für das Geschäftsjahr 2014, das ... und eingereicht. Das Unternehmen hat die ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
Breaking Biology Technology:Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2
... 22 Techne Corporation,s,(Nasdaq: TECH ) consolidated net ... to $28.6 million or $.74 per diluted share,compared with ... quarter ended,September 30, 2007. Net earnings as a percentage ... of last year to 41.2% for the quarter ended,September ...
... Inc.,(Nasdaq: MDVN ) today announced that the ... its collaboration with,Pfizer Inc. expired on October 20, ... to jointly develop and commercialize,Dimebon for the treatment ... waiting period triggers an up-front payment to Medivation,of ...
... ,silent killers, such as ... Screenings provide potentially life-saving data, including actual images ... and their doctors ... Oct. 22 HealthYes!(TM), based in Austin,is a premier ...
Cached Biology Technology:Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 2Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 3Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 4Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009 5Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 2HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 3HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 4HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 5HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 6HealthYes! - Premier Provider of Mobile Preventive Medical Screenings - Launches in Alamo City 7
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... (March 14, 2012) A research team has identified ... in gene expression, within reprogrammed skin cells. These signatures ... reprogrammed skin cells or induced pluripotent stem cells (iPSCs), ... how the expression of the protein is controlled brings ...
... A new research survey conducted by the Center for ... Center shows the Bangladeshi community in New York City experiences ... and lack of diabetes awareness. The study, published in the ... Health , also found the Bangladeshi community has an interest ...
... Scientists at Johannes Gutenberg University Mainz (JGU) in ... proteins. Detailed knowledge of the dynamics of proteins is ... that occur on the molecular level. To date, this ... with fluorescent substances, but unfortunately this changes the proteins ...
Cached Biology News:Epigenetic signatures direct the repair potential of reprogrammed cells 2New study shines light on barriers to diabetes care in NYC Bangladeshi community 2Gold nanoantennas detect proteins 2
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: